Evaluation of opioid receptor subtype antagonist effects in the ventral tegmental area upon food intake under deprivation, glucoprivic and palatable conditions

Opioid receptor subtype antagonists differentially alter food intake under deprivation (24 h), glucoprivic (2-deoxy- d-glucose, 500 mg/kg, i.p.) or palatable (10% sucrose) conditions with μ (β-funaltrexamine) and κ (nor-binaltorphamine), but not δ 1 ([ d-Ala 2,Leu 5,Cys 6]enkephalin) opioid antagoni...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain research 1997-08, Vol.767 (1), p.8-16
Hauptverfasser: Ragnauth, Andre, Ruegg, Hildegard, Bodnar, Richard J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 16
container_issue 1
container_start_page 8
container_title Brain research
container_volume 767
creator Ragnauth, Andre
Ruegg, Hildegard
Bodnar, Richard J.
description Opioid receptor subtype antagonists differentially alter food intake under deprivation (24 h), glucoprivic (2-deoxy- d-glucose, 500 mg/kg, i.p.) or palatable (10% sucrose) conditions with μ (β-funaltrexamine) and κ (nor-binaltorphamine), but not δ 1 ([ d-Ala 2,Leu 5,Cys 6]enkephalin) opioid antagonists reducing each form of intake following ventricular microinjection. Both μ and κ opioid antagonists microinjected into either the hypothalamic paraventricular nucleus or the nucleus accumbens reduce intake under deprivation and glucoprivic conditions. Palatable intake is reduced by both antagonists in the paraventricular nucleus, but only μ antagonists are active in the accumbens. Food intake is stimulated by μ and δ, but not κ, opioid agonists microinjected into the ventral tegmental area. The present study examined whether food intake under either deprivation, glucoprivic or palatable conditions was altered by bilateral administration of general (naltrexone), μ, κ, δ 1 or δ 2 (naltrindole isothiocyanate) opioid antagonists into the ventral tegmental area. Deprivation (24 h)-induced feeding was significantly reduced by high (50 μg), but not lower (10–20 μg) doses of naltrexone (21%), and by δ 2 (4 μg, 19%) antagonism in the ventral tegmental area. 2-Deoxy- d-glucose (500 mg/kg, i.p.)-induced hyperphagia was significantly reduced by high (50 μg), but not lower (20 μg) doses of naltrexone (64%), and by δ 2 (4 μg, 27%) antagonism in the ventral tegmental area. Sucrose (10%) intake was significantly reduced by naltrexone (20–50 μg, 25–39%) and δ 2 (4 μg, 25%) antagonism in the ventral tegmental area. Neither μ, κ nor δ 1 antagonists were effective in reducing any form of intake following microinjection into the ventral tegmental area. These data indicate that the ventral tegmental area plays a relatively minor role in the elicitation of these forms of food intake, and that δ 2, rather than μ, κ or δ 1 opioid receptors appear responsible for mediation of these forms of intake by this nucleus.
doi_str_mv 10.1016/S0006-8993(97)00539-8
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79405093</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006899397005398</els_id><sourcerecordid>16059080</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-583782f687fed8bd4a52d3c51a7a9ec1e072fbca591326b0964dc1de6de3fde33</originalsourceid><addsrcrecordid>eNqFkcuKFTEQhoMo43H0EQayEgVbK51Od2clwzBeYMCFug7ppHKM9knaJH1gnsZXNefCbGdRVBX1V_0kHyFXDN4zYP2H7wDQN6OU_I0c3gIILpvxCdmwcWibvu3gKdk8SJ6TFzn_ri3nEi7IheS9AAYb8u92r-dVFx8DjY7GxUdvaUKDS4mJ5nUq9wtSHYrexuBzoegcmpKpD7T8QrrHUJKeacHtrpa10gk1XZd60MVoq67oP0jXYDFRi0vy-6PdO7qdVxMPvTfVwNJFz7roaUZqYrD-IMovyTOn54yvzvmS_Px0--PmS3P37fPXm-u7xnRiKI0Y-TC2rh8Hh3acbKdFa7kRTA9aomEIQ-smo4VkvO0nkH1nDbPYW-SuBr8kr093lxT_rpiL2vlscJ51wLhmNcgOBMjHhawHIWGEKhQnoUkx54RO1afudLpXDNSBoDoSVAc8Sg7qSFCNde_qbLBOO7QPW2dkdf7xNMf6HXuPSWXjMRi0vmIrykb_iMN_9kCwBg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16059080</pqid></control><display><type>article</type><title>Evaluation of opioid receptor subtype antagonist effects in the ventral tegmental area upon food intake under deprivation, glucoprivic and palatable conditions</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Ragnauth, Andre ; Ruegg, Hildegard ; Bodnar, Richard J.</creator><creatorcontrib>Ragnauth, Andre ; Ruegg, Hildegard ; Bodnar, Richard J.</creatorcontrib><description>Opioid receptor subtype antagonists differentially alter food intake under deprivation (24 h), glucoprivic (2-deoxy- d-glucose, 500 mg/kg, i.p.) or palatable (10% sucrose) conditions with μ (β-funaltrexamine) and κ (nor-binaltorphamine), but not δ 1 ([ d-Ala 2,Leu 5,Cys 6]enkephalin) opioid antagonists reducing each form of intake following ventricular microinjection. Both μ and κ opioid antagonists microinjected into either the hypothalamic paraventricular nucleus or the nucleus accumbens reduce intake under deprivation and glucoprivic conditions. Palatable intake is reduced by both antagonists in the paraventricular nucleus, but only μ antagonists are active in the accumbens. Food intake is stimulated by μ and δ, but not κ, opioid agonists microinjected into the ventral tegmental area. The present study examined whether food intake under either deprivation, glucoprivic or palatable conditions was altered by bilateral administration of general (naltrexone), μ, κ, δ 1 or δ 2 (naltrindole isothiocyanate) opioid antagonists into the ventral tegmental area. Deprivation (24 h)-induced feeding was significantly reduced by high (50 μg), but not lower (10–20 μg) doses of naltrexone (21%), and by δ 2 (4 μg, 19%) antagonism in the ventral tegmental area. 2-Deoxy- d-glucose (500 mg/kg, i.p.)-induced hyperphagia was significantly reduced by high (50 μg), but not lower (20 μg) doses of naltrexone (64%), and by δ 2 (4 μg, 27%) antagonism in the ventral tegmental area. Sucrose (10%) intake was significantly reduced by naltrexone (20–50 μg, 25–39%) and δ 2 (4 μg, 25%) antagonism in the ventral tegmental area. Neither μ, κ nor δ 1 antagonists were effective in reducing any form of intake following microinjection into the ventral tegmental area. These data indicate that the ventral tegmental area plays a relatively minor role in the elicitation of these forms of food intake, and that δ 2, rather than μ, κ or δ 1 opioid receptors appear responsible for mediation of these forms of intake by this nucleus.</description><identifier>ISSN: 0006-8993</identifier><identifier>EISSN: 1872-6240</identifier><identifier>DOI: 10.1016/S0006-8993(97)00539-8</identifier><identifier>PMID: 9365010</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Deoxyglucose - pharmacology ; Eating - drug effects ; Enkephalin, Leucine-2-Alanine - analogs &amp; derivatives ; Enkephalin, Leucine-2-Alanine - pharmacology ; Evaluation Studies as Topic ; Food Deprivation ; Glucoprivic intake ; Hyperphagia - chemically induced ; Insulin - pharmacology ; Naltrexone - analogs &amp; derivatives ; Naltrexone - pharmacology ; Narcotic Antagonists - pharmacology ; Palatability ; Sucrose - pharmacology ; Ventral tegmental area ; Ventral Tegmental Area - drug effects ; δ 1 Opioid receptor ; δ 2 Opioid receptor ; κ Opioid receptor ; μ Opioid receptor</subject><ispartof>Brain research, 1997-08, Vol.767 (1), p.8-16</ispartof><rights>1997 Elsevier Science B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c457t-583782f687fed8bd4a52d3c51a7a9ec1e072fbca591326b0964dc1de6de3fde33</citedby><cites>FETCH-LOGICAL-c457t-583782f687fed8bd4a52d3c51a7a9ec1e072fbca591326b0964dc1de6de3fde33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0006-8993(97)00539-8$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9365010$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ragnauth, Andre</creatorcontrib><creatorcontrib>Ruegg, Hildegard</creatorcontrib><creatorcontrib>Bodnar, Richard J.</creatorcontrib><title>Evaluation of opioid receptor subtype antagonist effects in the ventral tegmental area upon food intake under deprivation, glucoprivic and palatable conditions</title><title>Brain research</title><addtitle>Brain Res</addtitle><description>Opioid receptor subtype antagonists differentially alter food intake under deprivation (24 h), glucoprivic (2-deoxy- d-glucose, 500 mg/kg, i.p.) or palatable (10% sucrose) conditions with μ (β-funaltrexamine) and κ (nor-binaltorphamine), but not δ 1 ([ d-Ala 2,Leu 5,Cys 6]enkephalin) opioid antagonists reducing each form of intake following ventricular microinjection. Both μ and κ opioid antagonists microinjected into either the hypothalamic paraventricular nucleus or the nucleus accumbens reduce intake under deprivation and glucoprivic conditions. Palatable intake is reduced by both antagonists in the paraventricular nucleus, but only μ antagonists are active in the accumbens. Food intake is stimulated by μ and δ, but not κ, opioid agonists microinjected into the ventral tegmental area. The present study examined whether food intake under either deprivation, glucoprivic or palatable conditions was altered by bilateral administration of general (naltrexone), μ, κ, δ 1 or δ 2 (naltrindole isothiocyanate) opioid antagonists into the ventral tegmental area. Deprivation (24 h)-induced feeding was significantly reduced by high (50 μg), but not lower (10–20 μg) doses of naltrexone (21%), and by δ 2 (4 μg, 19%) antagonism in the ventral tegmental area. 2-Deoxy- d-glucose (500 mg/kg, i.p.)-induced hyperphagia was significantly reduced by high (50 μg), but not lower (20 μg) doses of naltrexone (64%), and by δ 2 (4 μg, 27%) antagonism in the ventral tegmental area. Sucrose (10%) intake was significantly reduced by naltrexone (20–50 μg, 25–39%) and δ 2 (4 μg, 25%) antagonism in the ventral tegmental area. Neither μ, κ nor δ 1 antagonists were effective in reducing any form of intake following microinjection into the ventral tegmental area. These data indicate that the ventral tegmental area plays a relatively minor role in the elicitation of these forms of food intake, and that δ 2, rather than μ, κ or δ 1 opioid receptors appear responsible for mediation of these forms of intake by this nucleus.</description><subject>Deoxyglucose - pharmacology</subject><subject>Eating - drug effects</subject><subject>Enkephalin, Leucine-2-Alanine - analogs &amp; derivatives</subject><subject>Enkephalin, Leucine-2-Alanine - pharmacology</subject><subject>Evaluation Studies as Topic</subject><subject>Food Deprivation</subject><subject>Glucoprivic intake</subject><subject>Hyperphagia - chemically induced</subject><subject>Insulin - pharmacology</subject><subject>Naltrexone - analogs &amp; derivatives</subject><subject>Naltrexone - pharmacology</subject><subject>Narcotic Antagonists - pharmacology</subject><subject>Palatability</subject><subject>Sucrose - pharmacology</subject><subject>Ventral tegmental area</subject><subject>Ventral Tegmental Area - drug effects</subject><subject>δ 1 Opioid receptor</subject><subject>δ 2 Opioid receptor</subject><subject>κ Opioid receptor</subject><subject>μ Opioid receptor</subject><issn>0006-8993</issn><issn>1872-6240</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcuKFTEQhoMo43H0EQayEgVbK51Od2clwzBeYMCFug7ppHKM9knaJH1gnsZXNefCbGdRVBX1V_0kHyFXDN4zYP2H7wDQN6OU_I0c3gIILpvxCdmwcWibvu3gKdk8SJ6TFzn_ri3nEi7IheS9AAYb8u92r-dVFx8DjY7GxUdvaUKDS4mJ5nUq9wtSHYrexuBzoegcmpKpD7T8QrrHUJKeacHtrpa10gk1XZd60MVoq67oP0jXYDFRi0vy-6PdO7qdVxMPvTfVwNJFz7roaUZqYrD-IMovyTOn54yvzvmS_Px0--PmS3P37fPXm-u7xnRiKI0Y-TC2rh8Hh3acbKdFa7kRTA9aomEIQ-smo4VkvO0nkH1nDbPYW-SuBr8kr093lxT_rpiL2vlscJ51wLhmNcgOBMjHhawHIWGEKhQnoUkx54RO1afudLpXDNSBoDoSVAc8Sg7qSFCNde_qbLBOO7QPW2dkdf7xNMf6HXuPSWXjMRi0vmIrykb_iMN_9kCwBg</recordid><startdate>19970829</startdate><enddate>19970829</enddate><creator>Ragnauth, Andre</creator><creator>Ruegg, Hildegard</creator><creator>Bodnar, Richard J.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>19970829</creationdate><title>Evaluation of opioid receptor subtype antagonist effects in the ventral tegmental area upon food intake under deprivation, glucoprivic and palatable conditions</title><author>Ragnauth, Andre ; Ruegg, Hildegard ; Bodnar, Richard J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-583782f687fed8bd4a52d3c51a7a9ec1e072fbca591326b0964dc1de6de3fde33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Deoxyglucose - pharmacology</topic><topic>Eating - drug effects</topic><topic>Enkephalin, Leucine-2-Alanine - analogs &amp; derivatives</topic><topic>Enkephalin, Leucine-2-Alanine - pharmacology</topic><topic>Evaluation Studies as Topic</topic><topic>Food Deprivation</topic><topic>Glucoprivic intake</topic><topic>Hyperphagia - chemically induced</topic><topic>Insulin - pharmacology</topic><topic>Naltrexone - analogs &amp; derivatives</topic><topic>Naltrexone - pharmacology</topic><topic>Narcotic Antagonists - pharmacology</topic><topic>Palatability</topic><topic>Sucrose - pharmacology</topic><topic>Ventral tegmental area</topic><topic>Ventral Tegmental Area - drug effects</topic><topic>δ 1 Opioid receptor</topic><topic>δ 2 Opioid receptor</topic><topic>κ Opioid receptor</topic><topic>μ Opioid receptor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ragnauth, Andre</creatorcontrib><creatorcontrib>Ruegg, Hildegard</creatorcontrib><creatorcontrib>Bodnar, Richard J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ragnauth, Andre</au><au>Ruegg, Hildegard</au><au>Bodnar, Richard J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of opioid receptor subtype antagonist effects in the ventral tegmental area upon food intake under deprivation, glucoprivic and palatable conditions</atitle><jtitle>Brain research</jtitle><addtitle>Brain Res</addtitle><date>1997-08-29</date><risdate>1997</risdate><volume>767</volume><issue>1</issue><spage>8</spage><epage>16</epage><pages>8-16</pages><issn>0006-8993</issn><eissn>1872-6240</eissn><abstract>Opioid receptor subtype antagonists differentially alter food intake under deprivation (24 h), glucoprivic (2-deoxy- d-glucose, 500 mg/kg, i.p.) or palatable (10% sucrose) conditions with μ (β-funaltrexamine) and κ (nor-binaltorphamine), but not δ 1 ([ d-Ala 2,Leu 5,Cys 6]enkephalin) opioid antagonists reducing each form of intake following ventricular microinjection. Both μ and κ opioid antagonists microinjected into either the hypothalamic paraventricular nucleus or the nucleus accumbens reduce intake under deprivation and glucoprivic conditions. Palatable intake is reduced by both antagonists in the paraventricular nucleus, but only μ antagonists are active in the accumbens. Food intake is stimulated by μ and δ, but not κ, opioid agonists microinjected into the ventral tegmental area. The present study examined whether food intake under either deprivation, glucoprivic or palatable conditions was altered by bilateral administration of general (naltrexone), μ, κ, δ 1 or δ 2 (naltrindole isothiocyanate) opioid antagonists into the ventral tegmental area. Deprivation (24 h)-induced feeding was significantly reduced by high (50 μg), but not lower (10–20 μg) doses of naltrexone (21%), and by δ 2 (4 μg, 19%) antagonism in the ventral tegmental area. 2-Deoxy- d-glucose (500 mg/kg, i.p.)-induced hyperphagia was significantly reduced by high (50 μg), but not lower (20 μg) doses of naltrexone (64%), and by δ 2 (4 μg, 27%) antagonism in the ventral tegmental area. Sucrose (10%) intake was significantly reduced by naltrexone (20–50 μg, 25–39%) and δ 2 (4 μg, 25%) antagonism in the ventral tegmental area. Neither μ, κ nor δ 1 antagonists were effective in reducing any form of intake following microinjection into the ventral tegmental area. These data indicate that the ventral tegmental area plays a relatively minor role in the elicitation of these forms of food intake, and that δ 2, rather than μ, κ or δ 1 opioid receptors appear responsible for mediation of these forms of intake by this nucleus.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>9365010</pmid><doi>10.1016/S0006-8993(97)00539-8</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0006-8993
ispartof Brain research, 1997-08, Vol.767 (1), p.8-16
issn 0006-8993
1872-6240
language eng
recordid cdi_proquest_miscellaneous_79405093
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Deoxyglucose - pharmacology
Eating - drug effects
Enkephalin, Leucine-2-Alanine - analogs & derivatives
Enkephalin, Leucine-2-Alanine - pharmacology
Evaluation Studies as Topic
Food Deprivation
Glucoprivic intake
Hyperphagia - chemically induced
Insulin - pharmacology
Naltrexone - analogs & derivatives
Naltrexone - pharmacology
Narcotic Antagonists - pharmacology
Palatability
Sucrose - pharmacology
Ventral tegmental area
Ventral Tegmental Area - drug effects
δ 1 Opioid receptor
δ 2 Opioid receptor
κ Opioid receptor
μ Opioid receptor
title Evaluation of opioid receptor subtype antagonist effects in the ventral tegmental area upon food intake under deprivation, glucoprivic and palatable conditions
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A49%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20opioid%20receptor%20subtype%20antagonist%20effects%20in%20the%20ventral%20tegmental%20area%20upon%20food%20intake%20under%20deprivation,%20glucoprivic%20and%20palatable%20conditions&rft.jtitle=Brain%20research&rft.au=Ragnauth,%20Andre&rft.date=1997-08-29&rft.volume=767&rft.issue=1&rft.spage=8&rft.epage=16&rft.pages=8-16&rft.issn=0006-8993&rft.eissn=1872-6240&rft_id=info:doi/10.1016/S0006-8993(97)00539-8&rft_dat=%3Cproquest_cross%3E16059080%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16059080&rft_id=info:pmid/9365010&rft_els_id=S0006899397005398&rfr_iscdi=true